GlassScriptPhysician profile
Jeff B Hales
NPI 1457344764
$36,834.51
in general payments reported to CMS, 2019-2025
48 companies · $16K in 2025
The $16K reported for 2025 was more than what 96% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,921 · 2020: $2,967 · 2021: $3,401 · 2022: $2,228 · 2023: $1,728 · 2024: $2,690 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $6,306 · Travel and Lodging: $1,176 · Education: $468 · Gift: $17.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,350.00 |
| Food and Beverage | $6,306.29 |
| Travel and Lodging | $1,176.11 |
| Education | $467.88 |
| Gift | $17.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $15,585.33 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Insmed, INC. | $13,579.08 | 2019-2025 | Arikayce, Brinsupri |
| Astrazeneca Pharmaceuticals LP | $1,854.59 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Genzyme Corporation | $508.93 | 2019-2025 | |
| Amgen INC. | $458.24 | 2022-2025 | Tezspire |
| United Therapeutics Corporation | $421.95 | 2021-2025 | Tyvaso, Remodulin, Tyvaso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $403.50 | 2019-2024 | Ofev, Spiriva Respimat |
| Genentech USA, INC. | $381.79 | 2019-2025 | Xolair |
| Shionogi INC | $294.10 | 2024-2025 | Fetroja |
| Sanofi-Aventis U.S. LLC | $293.89 | 2024-2025 | |
| Mylan Specialty L.P. | $272.35 | 2019-2024 | Yupelri |
| Grifols USA, LLC | $240.25 | 2019-2025 | Prolastin-C Liquid |
| Electromed, INC. | $239.60 | 2019-2025 | Smartvest |
| Takeda Pharmaceuticals U.S.A., INC. | $238.76 | 2020-2025 | Glassia |
| Axsome Therapeutics, INC. | $177.81 | 2023-2025 | Sunosi |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeff Hales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.